VIP (Vasoactive Intestinal Peptide) – Comprehensive Research Overview (2026)
VIP (Vasoactive Intestinal Peptide) is a naturally occurring 28-amino-acid neuropeptide found throughout the nervous system, gut, and immune tissues. It acts as a potent vasodilator, bronchodilator, and immunomodulator, and plays key roles in circadian rhythm regulation, neuroinflammation, and gut motility. VIP is researched for autoimmune diseases, inflammatory conditions, pulmonary hypertension, MCAS (mast cell activation syndrome), and long COVID-associated dysautonomia.
→ View VIP (for laboratory research use only)
Mechanism of Action
- Binds VPAC1 and VPAC2 receptors (G-protein coupled), activating cAMP signaling.
- Potent vasodilation and bronchodilation via smooth muscle relaxation.
- Anti-inflammatory: suppresses TNF-α, IL-6, IL-12; promotes IL-10 and regulatory T cells.
- Modulates circadian rhythms via the suprachiasmatic nucleus (SCN).
- Regulates gut motility, secretion, and mucosal immunity.
Clinical Evidence and Research Findings
VIP has been studied in pulmonary arterial hypertension (PAH), where inhaled VIP showed improvements in hemodynamics and exercise capacity in early trials. Growing research interest in MCAS, long COVID, and dysautonomia, where VIP deficiency has been proposed as a contributing factor. Anti-inflammatory and immunomodulatory properties are well-established in preclinical models.
→ Interested in researching VIP? View Product Options
Benefits (Research & Clinical Observations)
- Potent anti-inflammatory and immunomodulatory effects
- Vasodilation and pulmonary hemodynamic improvement
- Gut motility and mucosal health support
- Circadian rhythm regulation
- Potential for MCAS, long COVID, and dysautonomia research
Typical Dosing Protocols (Research)
- Inhaled (PAH research): 100 nmol inhaled 4× daily
- Subcutaneous (off-label): 50–200 μg once or twice daily
- Short half-life (~2 minutes IV); subcutaneous provides longer exposure
Safety Profile and Side Effects
VIP has a favorable safety profile in clinical studies. Common side effects: facial flushing, mild hypotension, transient GI effects. Generally well-tolerated at research doses.
Summary
VIP is a pleiotropic neuropeptide with potent anti-inflammatory, vasodilatory, and immunomodulatory properties. Its emerging role in MCAS, long COVID, and dysautonomia research makes it one of the most clinically relevant peptides in current investigation. As with all compounds in this library, VIP is not an approved drug for these indications and should only be considered under qualified medical supervision.
For Laboratory Research Use View VIP →
Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.